Sigachi IndustriesQ3 FY24

Sigachi Industries Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹28.61P/E: 43.7Market Cap: ₹1.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • Sigachi Industries aims for around 30% revenue growth for FY24-25 due to capex and API segment expansion.
  • Historically, the company has grown at a 25% CAGR, with expectations of slightly higher growth in current fiscal.
  • Capacity expansion from 14,000 tons to 21,000 tons for MCC will boost production volumes and revenue.
  • The company expects to surpass INR 600 crores in sales around FY25-26, driven by expanded capacity and API business.
  • MCC quantity increased by 12% YoY (from 9,851 MT to 11,036 MT) with current utilization about 90-95%.
  • Growth drivers include strong pharma demand for excipients (MCC/CCS) and increased contribution from API manufacturing.
  • API segment targeted to achieve positive EBITDA margins and contribute substantially to overall revenue mix.
  • O&M and subsidiaries like Sigachi US are also contributing to growth, with O&M revenue rising from INR 13.3 crores to INR 35 crores over three years.

See what Sigachi Industries management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • The company has issued share warrants totaling INR 286.45 crores for capital expenditure and acquisitions, including INR 160 crores for acquisition and expansion of API facility (Trimax Bio Sciences), INR 50 crores for Dahej and Jhagadia expansion, and INR 22 crores for augmentation of Hyderabad unit.
  • These share warrants are issued to a group of investors including promoters, with a standard 18-month conversion term.
  • Additional funds are planned through retained earnings, further equity infusion, or debt.
  • Promoter pledging of shares was done solely to raise money for further investment, which was infused back into the company.
  • The company is optimistic about using a mix of retained earnings, equity, and debt to fund ongoing INR 200 crores capex over FY24 and FY25.
  • There is no explicit recent announcement of fresh debt fundraise, but a mix of funding methods is contemplated.

See what Sigachi Industries management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Total planned capex is around INR 200 crores: INR 100 crores in FY24 and INR 100 crores in FY25.
  • INR 160 crores out of this is allocated towards acquisition and expansion of the API facility, specifically Trimax Bio Sciences at Raichur.
  • INR 50 crores allocated for expansion of Dahej and Jhagadia units.
  • INR 22 crores planned for augmentation of the Hyderabad unit.
  • Additional funds raised through share warrants (INR 286.45 crores issued) and other sources like retained earnings or debt.
  • The capex is expected to take time to capitalize and show results due to necessary validations and commissioning.
  • CCS (Croscarmellose Sodium) project capex delayed due to environmental clearance but expected to be deployed by March, with commissioning over next 18 months.
  • MCC plant capacity expansion underway, increasing capacity from 14,000 to 21,000 metric tons, expected to start sales from end of February.

Track Sigachi Industries — get its next earnings analysis in your feed

How does Sigachi Industries rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSigachi Industries
Rev 2Mar 1

How does Sigachi Industries rank in Pharmaceuticals & Biotechnology?

Compare Sigachi Industries against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →